Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay

Analytical Biochemistry

Volumn 275, Issue 1, 1999, Pages 84-92

  Labuda, Damian ^a   Krajinovic, Maja ^b   Richer, Chantal ^b   Skoll, Amanda ^a   Sinnett, Hugues ^b   Yotova, Vania ^b   Sinnett, Daniel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE

Author keywords

DNA polymorphisms; Genotyping; Multiplex PCR ASO; Xenobiotics metabolism

Indexed keywords

BIOCHEMISTRY; COST EFFECTIVENESS; DNA; GENES; METABOLISM; OLIGONUCLEOTIDES; POPULATION STATISTICS;

DNA POLYMORPHISM; FUNCTIONAL POLYMORPHISMS; GENOTYPING; METABOLIC CONVERSION; MULTIPLEX PCR; NUMBER OF SAMPLES; OXIDATIVE METABOLISM; ROBOTIC WORKSTATION;

POLYMERASE CHAIN REACTION;

ACYLTRANSFERASE; CYTOCHROME P450 ISOENZYME; OLIGONUCLEOTIDE;

AEROBIC METABOLISM; ARTICLE; AUTOMATION; CANCER SUSCEPTIBILITY; CONJUGATION; COST EFFECTIVENESS ANALYSIS; DNA HYBRIDIZATION; DNA POLYMORPHISM; GENE AMPLIFICATION; GENOTYPE; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0033230795     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1006/abio.1999.4293     Document Type: Article

References (38)

1. Kawajiri K., Nakachi K., Imai K., Yoshii A., Shinoda N., Watanabe J. Identification of genetically high-risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IAI gene. FEBS Lett. 263:1990;131.
2. Hayashi S. I., Watanabe J., Nakachi K., Kawajiri K. Genetic linkage of lung cancer-associated Msp1 polymorphism with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene. J. Biochem. 110:1991;407.
3. Cascorbi I., Brockmöller J., Roots A. C4887A polymorphism in exon 7 of human CYP1A1: Population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res. 56:1996;4965-4969.
4. Sachse C., Brockmöller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60:1997;284-295.
5. Cascorbi I., Drakoulis N., Brockmoller J., Maurer A., Sperling K., Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity. Am. J. Hum. Genet. 57:1995;581-592.
6. Lin H. J., Han C.-Y., Lin B. K., Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics. 4:1994;125-134.
7. Vatsis K. P., Weber W. W., Bell D. A., Dupret J.-M., Evans D. A. P., Grant D. M., Hein D. W., Lin H. J., Meyer U. A., Relling M. V., Sim E., Suzuki T., Yasuschi Y. Nomenclature for N-acetyltransferase. Pharmacogenetics. 5:1995;1-17.
8. Perera F. P. Molecular epidemiology: Insights into cancer susceptibility, risk assessment, and prevention. J. Natl. Cancer Inst. 88:1996;496-509.
9. Cosma G., Crofts F., Currie D., Wirgin I., Toniolo P., Garte S. J. Racial differences in restriction fragment length polymorphisms and messenger RNA inducibility of the human CYP1A1 gene. Cancer Epidemiol. Biomarkers Prev. 2:1993;53-57.
10. Taioli E., Crofts F., Trachman J., Bayo S., Toniolo P., Garte S. J. Racial differences in CYP1A1 genotype and function. Toxicol. Lett. 77:1995;357-362.
11. Cascorbi I., Brockmöller J., Mrozikiewicz P. M., Bauer S., Loddenkemper R., Roots I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor in lung cancer. Cancer Res. 56:1996;3961-3966.
12. Shields P. G., Bowman E. D., Harrington A. M., Doan V. T., Weston A. Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res. 53:1993;3486-3492.
13. Baccichet A., Qualman S. K., Sinnett D. Allelic loss in childhood acute lymphoblastic leukaemia. Leuk. Res. 21:1997;817.
14. Smith A. D., Gough A. C., Leigh P. N., Summers B. A., Harding A. E., Maranganore D. M., Sturman S. G., Schapira A. H. V., Williams A. C., Spurr N. K., Wolf C. R. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet. 339:1992;1375-1377.
15. Deitz A. C., Doll M. A., Hein D. W. A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles. Anal. Biochem. 253:1997;219-224.
16. Brockmöller J., Cascorbi I., Kerb R., Roots I. Combined analysis of Inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1, and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 56:1996;3915-3925.
17. Kimura S., Umeno M., Skoda R. C., Meyer U. A., Gonzalez F. J. The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet. 45:1989;889-904.
18. Zietkiewicz E., Yotova V., Jarnik M., Korab-Laskowska M., Kidd K. K., Modiano D., Scozzari R., Stoneking M., Tishkoff S., Batzer M., Labuda D. Nuclear DNA diversity in worldwide distributed human populations. Gene. 205:1997;161-171.
19. DeMarchi J. M., Richards C. S., Fenwick R. G., Pace R., Beaudet A. L. A robotics-assisted procedure for large scale cystic fibrosis mutation analysis. Hum. Mutat. 4:1994;287-290.
20. Hézard N., Cornillet-Lefebvre P., Gillot L., Potron G., Nguyen P. Multiplex ASO PCR for a simultaneous determination of factor V Leiden gene, G → A20210 prothrombin gene and C → T677 MTHFR gene mutations. Thromb. Haemost. 79:1998;1054-1055.
21. Wong L.-J. C., Senadheera D. Direct detection of multiple point mutations in mitochondrial DNA. Clin. Chem. 43:1997;1857-1861.
22. Krajinovic M., Labuda D., Richer C., Karimi S., Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: Influence of CYP1A1, CYP2D6, GSTM1 and GSTT1 genetic polymorphisms. Blood. 93:1999;1496-1501.
23. Evans D. A. P. N-Acetyltransferase. Pharmacol. Ther. 42:1989;157-234.
24. Bouchard G., De Braekeleer M. Histoire d'un Génome. 1990;Presses de l'Université du Québec.
25. Labuda D., Zietkiewicz E., Labuda M. The genetic clock and the age of the founder effect in growing populations: A lesson from French Canadians and Ashkenazim. Am. J. Hum. Genet. 61:1997;768-771.
26. Wang D. G., Fan J.-B., Siao C.-J., Berno A., Young P., Sapolsky R., Ghandour G., Perkins N., Winchester E., Spencer J., Kruglyak L., Stein L., Hsie L., Topaloglou T., Hubbell E., Robinson E., Mittmann M., Morris M. S., Shen N., Kilburn D., Rioux J., Nusbaum C., Rozen S., Hudson T. J., Lander E. S. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science. 280:1998;1077-1081.
27. Bell D., Taylor J., Butler M., Stephens E., Wiest J., Brubaker L., Kadlubar F., Lucier G. Genotype/phenotype discordance for human NAT2 reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis. 14:1993;1689-1692.
28. Millikan R. C., Pittman G. S., Newman B., Tse C.-K. J., Selmin O., Rockhill B., Savitz D., Moorman P. G., Bell D. A. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 7:1998;371-378.
29. Taylor J. A., Umbach D. M., Stephens E., Castranio T., Paulson D., Robertson C., Mohler J. L., Bell D. A. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: Evidence of a gene-gene-exposure three-way interaction. Cancer Res. 58:1998;3603-3610.
30. Bouchardy, C., Mitrunen, K., Wikman, H., Husgafvel-Pursiainen, K., Dayer, P., Benhamou, S., and Hirvonen, A.N-Acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics8, 291-298.
31. Bailey L. R., Roodi N., Verrier C. S., Yee C. J., Dupont W. D., Pair F. F. Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: Evidence of a lack of association in Caucasians and African Americans. Cancer Res. 58:1998;65-70.
32. Deloménie C., Grant D. M., Krishnamoorthy R., Dupret J. M. Les arylamine N-acétyltransferases: Génétique à la susceptibilité aux xénobiotiques. Med./Sci. 14:1998;27-36.
33. Katoh T., Kaneko S., Boissy R., Watson M., Ikemura K., Bell D. A. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis. 19:1998;1803-1807.
34. Leathart J. B. S., London S. J., Steward A., Adams J. D., Idle J. R., Daly A. K. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics. 8:1998;529-541.
35. Meyer U. A., Zanger U. M. Molecular mechanism of genetic polymorphism of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37:1997;269-296.
36. Sivaraman L., Leatham M. P., Yee J., Wilkens L. R., Lau A. F., Le Marchand L. CYP1A1 genetic polymorphisms and in situ colorectal cancer. Cancer Res. 54:1994;3692-3695.
37. Taioli E., Trachman J., Chen X., Toniolo P., Garte S. J. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res. 55:1995;3757-3758.
38. Zhao B., Lee E. J., Yeoh P. N., Gong N. H. Detection of mutations and polymorphism of N-acetyltransferase 1 gene in Indian, Malay and Chinese populations. Pharmacogenetics. 8:1998;299-304.